Skip to main content
. 2021 Aug 26;8(4):1603–1616. doi: 10.1007/s40744-021-00360-6

Fig. 2.

Fig. 2

Sensitivity meta-analysis of new IBD in anti-IL-17 spondyloarthritis trials, comparing event rates of 1/585 to 6/1177